The diabetes pandemic and associated infections: suggestions for clinical microbiology

Antonio Toniolo\textsuperscript{a}, Gianluca Cassani\textsuperscript{b}, Anna Puggioni\textsuperscript{b}, Agostino Rossi\textsuperscript{b}, Alberto Colombo\textsuperscript{b}, Takashi Onodera\textsuperscript{c} and Ele Ferrannini\textsuperscript{d}

There are 425 million people with diabetes mellitus in the world. By 2045, this figure will grow to over 600 million. Diabetes mellitus is classified among noncommunicable diseases. Evidence points to a key role of microbes in diabetes mellitus, both as infectious agents associated with the diabetic status and as possible causative factors of diabetes mellitus. This review takes into account the different forms of diabetes mellitus, the genetic determinants that predispose to type 1 and type 2 diabetes mellitus (especially those with possible immunologic impact), the immune dysfunctions that have been documented in diabetes mellitus. Common infections occurring more frequently in diabetic vs. nondiabetic individuals are reviewed. Infectious agents that are suspected of playing an etiologic/triggering role in diabetes mellitus are presented, with emphasis on enteroviruses, the hygiene hypothesis, and the environment. Among biological agents possibly linked to diabetes mellitus, the gut microbiome, hepatitis C virus, and prion-like protein aggregates are discussed. Finally, preventive vaccines recommended in the management of diabetic patients are considered, including the bacillus calmette-Guerin vaccine that is being tested for type 1 diabetes mellitus. Evidence supports the notion that attenuation of immune defenses (both congenital and secondary to metabolic disturbances as well as to microangiopathy and neuropathy) makes diabetic people more prone to certain infections. Attentive microbiologic monitoring of diabetic patients is thus recommendable. As genetic predisposition cannot be changed, research needs to identify the biological agents that may have an etiologic role in diabetes mellitus, and to envisage curative and preventive ways to limit the diabetes pandemic.

Introduction

Due to increasing incidence worldwide, diabetes mellitus is a major medical problem. Diabetes mellitus is classified among noncommunicable diseases (NCDs) [1]. Strong evidence points to a key role of microbes in diabetes mellitus, both as infectious agents associated with the diabetic status and as possible causative factors of diabetes mellitus. Diabetes mellitus-related infections involve bacteria, viruses, fungi, parasites, and – possibly – prions.

Classification of diabetes mellitus

Diabetes mellitus includes a group of metabolic conditions characterized by hyperglycemia resulting from...
defects in insulin action, insulin secretion or both. Chronic hyperglycemia is associated with long-term damage and dysfunction of eyes, kidneys, blood vessels, nerves, and heart.

Table 1 summarizes the current classification of diabetes mellitus with the estimated global prevalence of different forms [3]. Type 2 diabetes mellitus (T2DM; classic or with relative insulin deficiency) accounts for over 80% of cases followed by latent autoimmune diabetes of the adult (LADA), an autoimmune form of diabetes defined by adult-onset and presence of diabetes-associated autoantibodies (especially glutamic acid decarboxylase p65, or GADA). LADA shares genetic features with both type 1 diabetes mellitus (T1DM) and T2DM. LADA patients have higher glycated hemoglobin (HbA1c) levels than T2DM patients, lower BMI, and more frequent, earlier need for insulin treatment than T2DM cases [4].

T1DM accounts for about 10% of cases. Secondary diabetes mellitus and the maturity-onset diabetes of the young account for less than 1% of cases. Gestational diabetes mellitus (GDM) is any degree of glucose intolerance with first recognition during pregnancy. GDM usually resolves after delivery but evolves to permanent diabetes mellitus in 5–10% of cases.

Impaired glucose tolerance (IGT) and impaired fasting glucose refer to individuals whose glucose levels are intermediate between normal values and values conventionally diagnostic of diabetes (Table 2). Collectively, these individuals are said to have ‘prediabetes’. The metabolic syndrome (insulin resistance, upper-body obesity, hypertension, hypertriglyceridemia, low levels of HDL cholesterol) identifies persons at high risk for glucose intolerance and diabetes mellitus [5].

Diagnosis requires a blood sample taken after an overnight (12–14-h) fast and/or the ingestion of a standard (75 g) glucose load oral glucose tolerance test. Plasma C-peptide/insulin levels and detection of diabetes-related autoantibodies are essential for identifying specific forms

| Forms of diabetes | Prevalence (%) |
|-------------------|----------------|
| Type 2 diabetes mellitus | |
| T2DM classic: fasting C-peptide >0.6 nmol/l (>1.82 ng/ml) | 80 |
| T2DM with relative insulin deficiency: fasting C-peptide 0.2–0.6 nmol/l (0.61–1.82 ng/ml) | 70 |
| LADA | 10 |
| LADA: autoimmune form of diabetes defined by age at onset >35 years, presence of diabetes-related autoantibodies, no insulin requirement for at least a period after diagnosis (www.actionlada.org) | 11 |
| Type 1 diabetes mellitus (immune-mediated or idiopathic) | |
| T1DM with absolute insulin deficiency: age at onset <35 years, fasting C-peptide <0.2 nmol/l (<0.61 ng/ml) | 7.9 |
| T1DM above 35 years | 6 |
| T1DM with relative insulin deficiency: fasting C-peptide 0.2–0.6 nmol/l (0.61–1.82 ng/ml) | 1.3 |
| ‘Fulminant diabetes’ with absolute insulin deficiency: abrupt onset, no diabetes-related autoantibodies, mainly reported from Asia | 0.1 |

Secondary diabetes mellitus

DM secondary to pancreas diseases: pancreatitis, trauma, pancreatectomy, neoplasia, cystic fibrosis, hereditary diabetes mellitus, fibrocystic pancreatopathy, other

DM secondary to endocrinopathies: acromegaly, Cushing’s syndrome, glucagonoma, pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma, other

DM caused by drugs or chemicals: vacor, pentamidine, nicotinic acid, glucocorticoids, thyroid hormone, diazoxide, β-adrenergic agonists, thiadiazine, dilantin, α-interferon, other

DM secondary to viral infections: congenital rubella, hepatitis C, Cytoegalovirus, other

DM associated with genetic syndromes: Down’s syndrome, Klinefelter’s syndrome, Turner’s syndrome, Wolfram’s syndrome, Friedreich’s ataxia, Huntington’s chorea, Laurence-Moon-Biedl syndrome, Myotonic dystrophy, Porphyria, Prader-Willi syndrome, other

DM due to genetic defects of insulin action and to uncommon causes: type-A insulin resistance, leprechaunism, Rabson-Mendenhall syndrome, lipodystrophic diabetes, ‘stiffman’ syndrome, antiinsulin receptor antibodies, other

MODY: hereditary forms of diabetes associated with mutations in an autosomal dominant gene disrupting insulin production

MODY 1: chromosome 20, HNF-4alpha

MODY 2: chromosome 7, glucokinase

MODY 3: chromosome 12, HNF-1alpha

MODY 4: chromosome 13, insulin promoter factor-1

MODY 5: chromosome 17, HNF-1beta

MODY 6: chromosome 2, NeuroD1

GDM: state of carbohydrate intolerance with onset or first recognition during pregnancy. Definition applies irrespective of whether the condition persists after pregnancy. Hyperglycemia usually resolves after delivery, but 5–10% of women may continue to have diabetes, often T2DM.

Prevalence not included

DM, diabetes mellitus; GDM, gestational diabetes mellitus; LADA, latent autoimmune diabetes of the adult; MODY, maturity-onset diabetes of the young; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus. Adapted from [2].
of diabetes mellitus. HbA1c is used both at diagnosis and during therapy.

The diabetes pandemic

Diabetes mellitus hits people at the most productive age, slows economic growth, reduces life-expectancy in elders, causes increasing healthcare expenditure. Diabetes mellitus is among the top 10 causes of death and (together with major NCDs – cardiovascular, cancer, respiratory disease) accounts for over 80% premature NCD deaths. Upon introduction of insulin, insulin-dependent people with diabetes started enjoying longer lives, but long-term complications emerged and T1DM became a chronic disease [5].

Current prevalence and perspectives

In developed countries, 87–91% of people with diabetes have T2DM, 7–12% have T1DM, 1–3% other types of diabetes mellitus [2,5]. As shown in Table 3, in the age group 20–79 (year 2017) there were 425 million people with diabetes worldwide. The figure is expected to increase to 629 million by 2045 [6]. Half of the people living with diabetes (49.7%) are undiagnosed and there were 352 million people with IGT, that is 7.3% of adults 20–79 years. By 2045, in the same age group the number of people with IGT is projected to 532 million (8.3% of adults). In 2017, 21.3 million live births were affected by some form of hyperglycemia in pregnancy. Worldwide, in the 20–99 years age range, approximately 5 million deaths/year are attributable to diabetes. In Europe (Table 4) the gross prevalence of diabetes mellitus ranges from 2.9% in Ireland to approximately 10% in Portugal and Bosnia–Herzegovina [2].

Healthcare costs

Based on 2017 data, the global healthcare expenditure on people with diabetes mellitus was estimated at USD 850 billion [6]. The cost of diagnosed diabetes mellitus in the United States has been USD 327 billion (including USD 90 billion for reduced productivity) and care for diabetes mellitus accounts for 1 in 4 healthcare dollars [9]. Over the last 5 years, cost has grown by 26%. In Lombardy

Table 2. Diagnostic criteria for prediabetes and diabetes (plasma glucose concentration).

| Diagnostic categories | Fasting plasma glucose | 2-h Plasma glucose | Random plasma glucose | Necessary criteria |
|-----------------------|------------------------|--------------------|-----------------------|--------------------|
| Prediabetes           |                        |                    |                       |                    |
| IFG                   | 6.1–6.9 mmol/l         | <7.8 mmol/l        | –                     | Both               |
| IGT                   | <7.0 mmol/l            | ≥7.8 and <11.1 mmol/l | –                     | Both               |
| T1DM                  | ≥12.6 mg/dl            | ≥140 and <200 mg/dl | –                     |                    |
| Diabetes              | ≥7.0 mmol/l            | ≥11.1 mmol/l       | ≥11.1 mmol/l          | One or more        |
|                       | ≥12.6 mg/dl            | ≥200 mg/dl         | ≥200 mg/dl            |                    |

Table 3. World: adults with diabetes in 2017 and projected figures for 2045.

| Population data                  | 2017       | 2045       |
|----------------------------------|------------|------------|
| Total world population           | 7.5 billion| 9.5 billion|
| Adult population (20–79 years)   | 4.8 billion| 6.4 billion|
| Number of people with diabetes (20–79 years) | 425 million | 629 million |
| Number of deaths due to diabetes (20–79 years) | 4.0 million | – |
| Number of people with impaired glucose tolerance (20–79 years) | 352 million | 532 million |
| Population (<20 years)           | 2.5 billion| –          |
| Number of children and adolescents with type 1 diabetes (0–19 years) | 1.1 million | – |

Adapted from [2].

Table 4. Adults with diabetes in ten European countries (2017).

| European countries | Population (thousands) | Adults with diabetes (thousands) | Diabetes prevalence (%) |
|--------------------|------------------------|----------------------------------|-------------------------|
| Germany            | 82 600.00              | 7476.80                          | 9.05                    |
| Spain              | 46 600.00              | 3584.53                          | 7.69                    |
| Italy              | 60 600.00              | 3402.34                          | 5.61                    |
| France             | 66 900.00              | 3276.42                          | 4.9                     |
| United Kingdom     | 65 640.00              | 2747.71                          | 4.19                    |
| Poland             | 37 950.00              | 2235.78                          | 5.89                    |
| Romania            | 19 700.00              | 1785.33                          | 9.06                    |
| Portugal           | 10 329.51              | 1063.03                          | 10.31                   |
| Netherlands        | 17 035.94              | 969.83                           | 5.69                    |
| Serbia             | 8790.57                | 858.9                            | 9.77                    |

Adapted from [2].
(Northern Italy) the average yearly expense per diabetic subject was 3300 Euro. Hospitalizations were the cost drivers contributing 54% of the total, followed by drugs (32%) and outpatient claims (14%) [10].

**Genetics of diabetes mellitus**

T1DM and T2DM are polygenic disorders, that is multiple genes contribute to their development [11,12]. Rare forms of diabetes mellitus (about 1% of cases) are single-gene disorders leading to beta cell or other defects [13].

**Genetic predisposition to type 1 diabetes mellitus**

The genetic basis of T1DM is well established, with more than 60 identified genes explaining ~80% of its heritability [14,15].

In the human leukocyte antigen (HLA) system, the primary disease risk determinant is the DQB1 gene, which encodes the beta chain of the Class II DQ molecule responsible for antigen presentation. Its alleles in combination with the neighboring DQA1 and DRB1 gene variants form the DR-DQ haplotypes that can be categorized into risk, neutral and protective groups (Table 5). The heterozygous combination of DR3-DQ2/DR4-DQ8 in terms of serological specificity (DRB103-DQA10501-DQB10201/DRB1*0401-DQA1*0301-DQB1*03 (DR3-DQ2/DR4-DQ8 in terms of serological specificity) represents the highest disease risk and is linked to approximately 50% of disease heritability in white people [14,16]. The DR15-DQ6 haplotype is protective. Different ethnic groups may have different HLA associations [11]. HLA Class II haplotypes are also linked to beta cell-specific autoantibody patterns: GADA are more frequent in patients with the HLA DR3-DQ2 haplotype, while insulin and IA-2 autoantibodies are associated with DR4-DQ8. Heritability is declining with increasing age at diagnosis [17].

Outside the HLA region, other predisposing gene variants have been identified by genome-wide association (GWAS) studies (e.g., INS, PTPN22, IL27, IFIH1 – Table 6). These genes are frequently involved in immune function and – possibly – in pathogenic pathways, for example, insulin expression in thymus, regulation of T-cell activation, innate virus immunity [28]. Thus, the risk of T1DM can be better predicted by using a genetic score that combines measurements of HLA and non-HLA loci [16].

**Genetic predisposition to type 2 diabetes mellitus**

Having a parent with diabetes increases the risk of developing diabetes mellitus by 30–40% [12]. GWAS studies have implicated more than 200 genomic regions in the predisposition to T2DM (i.e., there are common alleles with small cumulative effects on risk) [29]. In T2DM, genetic and environmental factors regulate the interplay between insulin sensitivity, appetite regulation, adipose storage, and beta cell failure [30]. Genes work by regulating a variety of aspects. For instance, the insulin-mediated glucose uptake in skeletal muscle (e.g., TBC1D4 gene), the ability to generate new adipocytes and the regulation of gene expression in these cells (e.g., PPARG, KLF14, IRS1 genes), lipoprotein lipase (LPL)-mediated lipolysis [31], insulin secretion either through beta cell dysfunction or through impaired beta cell development (e.g., KCNJ11, ABCC8). Table 7 lists a few implicated genes, some of which also play key roles in immunity. Thus, people carrying diabetes-predisposing gene variants are also likely to have flawed immune defenses. As in the case of T1DM, a genetic score combining measurements of multiple loci would be of help in assessing T2DM genetic risk.

**Immune dysfunction in diabetes**

Hyperglycemia is linked with both chronic inflammatory processes and diabetes mellitus-related vulnerability to infection. People with diabetes are more susceptible than people without diabetes to periodontal disease [41], tuberculosis (TB) [42], lung infection by *Legionella*

### Table 5. Type 1 diabetes mellitus: association with common human leukocyte antigen class II haplotypes.

| HLA class II haplotypes | Risk level | Notes |
|-------------------------|------------|-------|
| DRB1*04 DQA1*03 DQB1*0302 | Strong risk | DRB1 subtypes associated with variable risk |
| DRB1*0408 DQA1*03 DQB1*0304 | Strong risk | Rare haplotype |
| DRB1*03 DQA1*05 DQB1*02 | Risk | Stronger effect in Southern Europe |
| DRB1*0405 DQA1*03 DQB1*02 | Risk | Predominantly in the Mediterranean area |
| DRB1*09 DQA1*03 DQB1*0303 | Risk | Predominantly in Orientals |
| DRB1*0405 DQA1*03 DQB1*0401 | Risk | |
| DRB1*0802 DQA1*03 DQB1*0302 | Risk | |
| DRB1*07 DQA1*03 DQB1*02 | Risk | |
| DRB1*1501 DQA1*0102 DQB1*0301 | Protective | Predominantly in Blacks |

HLA genes play key roles in immunity. HLA, human leukocyte antigen. Adapted from [14].
Table 6. Major nonhuman leukocyte antigen genes predisposing to type 1 diabetes mellitus.

| Gene     | Chromosome | Functions                                                                 |
|----------|------------|---------------------------------------------------------------------------|
| INS      | 11p15.5    | Insulin: binding of insulin to the insulin receptor stimulates glucose uptake. Different mutant alleles with phenotypic effects have been identified. Single nucleotide polymorphisms may constitute risk factors for T1DM [18] |
| PTPN22   | 1p13.2     | Protein tyrosine phosphatase, nonreceptor type 22: lymphoid-specific intracellular phosphatase involved in the T-cell receptor signaling pathway. PTPN22 plays a role in regulating the function of immune cells, particularly T cells. Polymorphisms of PTPN22 have been associated with autoimmune diseases, including T1DM – immune function [19] |
| IL27     | 16p11.2    | IL-27: modulation of T-cell subsets and regulation of inflammatory response. Single nucleotide polymorphisms have been studied in relation to T1DM pathogenesis – immune function [20] |
| BAD      | 11q13.1    | BCL2-associated agonist of cell death: belongs to the BCL-2 family (regulators of apoptosis). Balance between pro-apoptotic proteins, such as BAD, and antiapoptotic proteins may play a role in hyperglycemia-induced β-cell apoptosis [21] |
| CD69     | 12p13.31   | CD69 molecule: member of the calcium dependent lectin superfamily of type II transmembrane receptors. Expression induced upon activation of T lymphocytes; may play a role in cell proliferation. Early lymphocyte activation antigen; limits the inflammatory response. Participates in signaling of natural killer cells. CD69 is related to multiple autoimmune diseases in children – immune function [22] |
| CLEC16A  | 16p11.13   | C-type lectin domain containing 16A: is expressed in NK, DC, B cells and beta cells. May be associated with increased susceptibility to T1DM, multiple sclerosis, adrenal dysfunction – immune function [23] |
| ERBB3    | 12q13.2    | Erb-b2 receptor tyrosine kinase 3: member of the epidermal growth factor receptor family; modulates antigen presentation, autoimmunity, cytokine-induced beta-cell apoptosis. A single nucleotide polymorphism in intron 7 seems associated with predisposition to T1DM – immune function [24] |
| CTSH     | 15q25.1    | Cathepsin H: lysosomal cysteine protease important in degradation of lysosomal proteins, apoptosis, TLR3 functions, antigen presentation, insulin synthesis in beta cells. CTSH may regulate β-cell function during T1DM progression – immune function [25] |
| IFIH1    | 2q24.2     | Interferon induced with helicase C domain 1: senses and initiates antiviral activity and is involved in inflammatory response in islets. IFIH1 polymorphisms seem associated with initial events of T1DM – immune function [26] |
| TYK2     | 19p13.2    | Tyrosine kinase 2: component of both type I and type III interferon signaling pathways. Plays a role in antiviral immunity. Loss-of-function variants reduce the response to interferons. Genetic variants seem associated to autoimmune diseases, including T1DM – immune function [27] |

Some genes may play a role in immunity. DC, dendritic cell; NK, natural killer; T1DM, type 1 diabetes mellitus. Adapted from [14,15].

Table 7. Major protein-coding genes and intron/intergenic variants associated with type 2 diabetes.

| Gene     | Chromosome | Functions                                                                 |
|----------|------------|---------------------------------------------------------------------------|
| TCF7L2   | 10q25.2    | Transcription factor 7 like 2: transcriptional effector of the Wnt/β-catenin signaling pathway that regulates adipogenesis and dendritic cell activation. Variants associated with increased risk of T2DM [32] – immune function [33] |
| JAZF1    | 7p15.1     | JAZ zinc finger 1: role in glucose homeostasis by improving glucose metabolism and insulin sensitivity; may also have antiapoptotic functions. Possible role for JAZF1 variants in T2D susceptibility in African-American individuals [34] |
| CDKN2A/2B| 9p21.3     | Cyclin dependent kinase inhibitor 2A/2B: causes cycle arrest in G1 and G2. Known as tumor suppressor, downregulates proliferation of normal cells interacting with CDK4/CDK6. Regulator of innate immunity. Correlation between CDKN2A/2B polymorphisms and predisposition to gestational diabetes – Immune function [35] |
| ADRA2A   | 10q25.2    | Adrenoreceptor alpha 2A: mediates catecholamine-induced inhibition of adenylate cyclase through G proteins. Involved in glucose homeostasis, antigen uptake, maturation of dendritic cells. Single nucleotide polymorphisms in or near ADRA2A, ADCY5, CDKAL1, CDKN2A/B, GRB10, TCF7L2 have effects on plasma glucose in childhood – immune function [36] |
| PPARC    | 3p25.2     | Peroxisome proliferator activated receptor gamma: promotes alveolar macrophage development. In dendritic cells and T cells drives pathogenic T2D responses in lung inflammation and allergy. The C/C genotype may predispose to diabetic nephropathy, while the G allele would be protective in T2DM patients – immune function [37] |
| SLC30A8  | 8q24.11    | Solute carrier family 30 member 8: zinc efflux transporter and zinc accumulation in intracellular vesicles. High-level expression only in pancreas, particularly islets. Variants confer susceptibility to T2DM [38] |
| PRKCO    | 10p15.1    | Protein kinase C theta: important for T-cell activation; interaction of APC with T cells. Diacylglycerol activation of PRKCO has a role in lipid-induced muscle insulin resistance in obese and T2DM – immune function [39] |
| ARG2     | 14q24.1    | Arginase 2: hydrolyzes arginine to ornithine and urea. Type II isoform located in mitochondria of extrahepatic tissues (kidney); role in nitric oxide and polyamine metabolism. Inhibition of arginase-2 might be effective for limiting diabetic renal injury. Modulates infection by H. pylori [40] |

Some variants may play a role in immunity. T2DM, type 2 diabetes mellitus. Adapted from [29].
pneumoniae [43], ‘mucormycosis’ caused by the Mucorales family of fungi [44]. Defects of the innate response come with dysfunction of granulocytes, monocyte/macrophages, dendritic cells, natural killer (NK) cells, B cells, T cells, and cytokine signaling.

Examples of immune defects associated to DM are summarized in Table 8. Hyperglycemia affects innate immunity by impeding production of type I interferon and IL22 [51,52]. Type I interferon has multiple effects, including antiviral activity [66], while IL22 reduces chronic inflammation and elicits antimicrobial immunity, preserves gut mucosal barrier, and improves insulin sensitivity [53]. Hyperglycemia also downregulates the expression of cathelicidins in macrophages (thereby implying diminished antimicrobial effects [54], reduces chemotaxis, impairs bacterial activity, and neutrophil degranulation in response to bacterial lipopolysaccharide (LPS) [57]. High glucose causes nonenzymatic glycation of multiple proteins, including those of the complement system involved in the opsonization of pathogens [49]. Glycation inhibits complement activation via the mannan-binding lectin pathway as well as functions of the CD59 inhibitor of the membrane attack complex [50]. Poor glycemic control also affects the production of reduced glutathione. Lack of reduced glutathione reduces the production of IL2 and IFN-γ by mononuclear cells with lessened killing of intracellular bacteria [55]. Protein glycation may favor bacterial growth by promoting the availability of micronutrients such as iron [56]. Long-term alterations of glucose homeostasis associate also with the formation of advanced glycation end-products (AGEs) that bind proteins, including albumin. AGE-albumin acts on neutrophils and macrophages by hindering trans-endothelial migration [47] and altering gene expression [48].

Neutrophils of people with diabetes show an elevated expression of peptidylarginine deiminase 4, a citrullinating enzyme involved in the release of the cell genome as neutrophil extracellular traps. Unbalanced NETosis promotes inflammation and has a negative impact on immune defenses and wound healing [45]. Reduced innate cell activation is seen in diabetes mellitus: peripheral blood mononuclear cells show an impaired production of IL1β a key mediator in inflammation [46,67]. In T1DM, elevated serum levels of IL15 and its soluble receptor (sIL15Rα) have been detected. As in other autoimmune conditions, the disordered expression of IL15 signaling may play a pathogenic role [60]. IL15 is a membrane-associated molecule that promotes the activation of NK and CD8 T-effector memory cells. Expression of IL15/IL15Rα occurs in viral infection (e.g., enterovirus-infected islets). In T1DM [63] and GDM [64] there may be reduced numbers of circulating NK cells and altered cytokine signaling. In visceral adipose tissue, conventional dendritic cells (cDCs) acquire a tolerogenic phenotype through upregulation of pathways involved in adipocyte differentiation. Although activation of the Wnt/β-catenin pathway in cDC1 DCs induces IL10 production (an anti-inflammatory mediator), upregulation of the PPARγ pathway in cDC2 DCs directly suppresses their activation. Combined, these effects promote an anti-inflammatory milieu that limits chronic inflammation and insulin resistance. However, with long-term over-nutrition, changes in adipocyte biology curtail β-catenin and PPARγ activation, contributing to persistent inflammation (Tables 8 and 9) [59].

Alterations of costimulatory molecules are also reported. Binding of CD40L on the surface of T cells to CD40 on the surface of antigen-presenting cells (dendritic cells, macrophages, B cells, other) activates immune responses. Plasma levels of sCD40L are elevated in hyperglycemic T2DM patients [70]. Binding of sCD40L to CD40 induces the production of proinflammatory cytokines, thus perpetuating the inflammatory status, perturbing insulin production, and downregulating antigen-specific responses [71].

In T1DM, beta cell damage is mediated by the combined actions of CD4+ and CD8+ T cells specific for islet autoantigens. T cell dysfunctions [especially FOXP3+ T regulatory cells (Tregs)] have been reported in the disease [61]. In addition, T cells responsive to beta cell autoantigens have an increased granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing component (GM-CSF+, IFNγ−, IL17A−, IL21−, IL22−, CD4 T cells) [62]. T2DM cases associated with lung TB are characterized by CD8 T cells exhibiting diminished expression of cytotoxic markers (perforin, granzyme B, CD107a) and, possibly, lessened antimicrobial activity [65]. B cells are also important: in T2DM patients as they promote inflammation through regulation of T-cell function and an inflammatory cytokine profile [72]. In T1DM, anti-CD20 therapy delays – but fails to prevent – the onset of the disease and B cells present autoantigens to T cells [73]. The numbers of B cells that infiltrate the pancreas correlate with β-cell loss [74]. The reported immune defects may be secondary to the functions of diabetes-predisposing alleles as shown for T1DM [75], and/or to metabolic alterations in lymphoid cells [76].

**Common infections and resistance to antimicrobial drugs**

Due to impaired defenses and disease complications, people with diabetes are prone to new infections and recurrences [urinary tract infection (UTI), periodontitis, pneumonia, skin, and soft tissue (including the diabetic foot), osteomyelitis, peritonitis]. Uncommon life-threatening infections are more frequent in people with diabetes than in people without diabetes (necrotizing soft tissue infection, emphysematous pyelonephritis,
emphysematous cholecystitis, malignant otitis, perioperative infection). Two recent chapters [68,77] and a review [78] cover the heightened susceptibility of people with diabetes to infections including tubercular mycobacteria [79,80]. Notably, the antimicrobial properties of metformin could reinforce antinfectious treatments in people with diabetes and metformin itself influences the composition of gut microbiome [81].

Common infections in people with diabetes are summarized in Table 9. Diabetes mellitus and HbA1c more than 6.5% are associated with the risk of community-acquired and hospital-acquired bloodstream infection and sepsis [82,83]. After recovery from sepsis, alterations in innate and adaptive immune responses endure, resulting in immune dysfunction, chronic inflammation, and microbial persistence that carries an increasing risk of postsepsis infections [84]. In a vicious cycle, infection can worsen glycemic control and vice versa. Glycation of FimH (an *Escherichia coli* adhesin in urinary tract epithelial cells) does enhance susceptibility to infection [85]. Similarly, expression of intercellular adhesion molecule-1 (ICAM-1) in vaginal cells is upregulated by high glucose, thus promoting adhesion of *Candida* spp. [86]. In people with diabetes with urinary tract infection (UTIs), elevated HbA1c levels represent a

| Table 8. Immune defects in diabetes (examples). |
|-----------------------------------------------|
| Associated condition | Target | Possible mechanism | Effect(s) |
|----------------------|--------|-------------------|----------|
| DM                   | Neutrophils | Excessive activation of peptidylarginine deiminase 4 and formation of NETs | NETosis promotes inflammation and interferes with immune defences and wound healing [43] |
|                      | Peripheral blood mononuclear cells | Reduced production of IL1beta | Diminished production of a key mediator of the inflammatory response [46] |
|                      | Albumin | Formation of AGE that bind proteins | AGE-albumin binds to neutrophils and macrophages obstructing trans-endothelial migration [47] and gene expression [48] |
|                      | Complement system | Nonenzymatic glycation of proteins | Defective opsonization of pathogens, decreased phagocytosis [49] |
|                      | Innate immunity | Unknown | Diminished production of cathelicidins, antimicrobial peptides [54] |
|                      | Macrophages | Unknown | Diminished production of IFN-I [51,52] |
|                      | Metabolism | Lack of reduced glutathione | Reduced activation of complement via mannose-binding lectins and interference with the CD59 inhibitor of complement-dependent cytolysis [50] |
|                      | Micronutrient-binding proteins | Nonenzymatic glycation of proteins | Downregulation of IL22 [51–53] |
|                      | Peripheral blood neutrophils | Unknown | Diminished production of cathelicidins, antimicrobial peptides [54] |
|                      | Peripheral blood phagocytes (?) | Unknown | Diminished production of IFN-alpha and IL2 with reduced killing of intracellular pathogens [55] |
| Long-term overnutrition | Conventional dendritic cells in visceral adipose tissue | Defective activation of beta-catenin and PPARgamma | Diminished production of a key mediator of the inflammatory response [46] |
| T1DM                 | Pancreatic islet cells (?) | Disordered expression of IL15 and its receptor molecule IL15Ralphalpha | Loss of tolerogenic phenotype in dendritic cells contributes to persistent inflammation [59] |
|                      | Peripheral blood T cells | Unknown | Expression of IL15 and IL15Ralphalpha on target allows NK and T effector cells to kill [60] |
|                      | T1DM and GDM | Peripheral blood NK cells | Diminished numbers of regulatory T cells [61] |
|                      | T2DM and hyperglycemia | Antigen-presenting cells and T cells | Increased numbers of CD4 cells producing GM-CSF [62] |
|                      | T2DM and tuberculosis | Cytotoxic T cells | Diminished antimiicrobial activity [65] |

AGE, advanced glycation end-product; DM, diabetes mellitus; GDM, gestational diabetes; GM-CSF, granulocyte-macrophage colony-stimulating factor; LPS, lipopolysaccharide; NET, neutrophil extracellular trap; NK, natural killer cells; T1DM, type-1 diabetes; T2DM, type 2 diabetes.
risk factor for bacteremia and sepsis [87]. In the course of dengue epidemics, people with diabetes are at risk for hemorrhagic fever [88].

Drug-resistant organisms and diabetes
Since people with diabetes are more exposed to antimicrobials than people without diabetes, drug-resistance is particularly prevalent in this group. Table 10 shows the prevalence of common drug-resistance phenotypes in bacterial isolates from patients diagnosed with infection worldwide (data of a 2015 1-day survey made in 53 countries) [69] compared with figures observed for people with diabetes mellitus at our own hospital in 2017 (Varese, Italy). Prevalence of resistance to common antibacterials is enhanced compared with nondiabetic patients. The prevalence of methicillin-resistant Staphylococcus aureus was high and comparable in both groups, confirming the extremely elevated prevalence of methicillin-resistant S. aureus strains in Italy [89]. In contrast, the prevalence of common resistance phenotypes (vancomycin-resistant enterococci, extended-spectrum β-lactamases-producing enterobacteria, carbapenem-resistant enterobacteria and nonfermenting Gram-negative bacilli) was more pronounced in people with diabetes vs. nondiabetic patients. Thus, early diagnosis and prompt treatment of infections are critical for people with diabetes, including surgical debridement when needed. Compared with people without diabetes, diabetes mellitus implies a higher risk of failure of Helicobacter pylori therapy, suggesting the need of specific regimens for its eradication [90].

Mycotic genital infections
People with diabetes are at an increased risk of being diagnosed with infections of the urogenital tract, especially individuals of younger age, with a history of prior genital infections, and with poorly controlled glycemia [91]. Candida spp. constitute the most frequent isolate [92]. The most recent addition to the therapeutic options for the treatment of T2DM are the sodium-glucose cotransporter 2 (SGLT2) inhibitors (three members of the class – canagliflozin, dapagliflozin, and empagliflozin currently marketed in Western countries).

Table 9. Common infectious events in people with diabetes.

| Body site                              | Infection                        | Etiologic agent(s)                                                                 |
|----------------------------------------|----------------------------------|-----------------------------------------------------------------------------------|
| Head and neck                          | Periodontal disease              | Oral commensals, Porphyromonas gingivalis, Tannerella forsythia, Streptococcus pneumonia, Enterobacteriaceae |
|                                        | Mucomycosis (zygomycosis)        | Rhizopus spp., Mucor spp.                                                        |
|                                        | Endophthalmitis                  | P. aeruginosa, Aspergillus spp. and other fungi                                  |
|                                        | Malignant otitis externa         | S. pneumoniae, S. aureus, K. pneumoniae and other Gram-negative bacilli           |
|                                        | Pneumonia and bronchopneumonia   | Legionella spp.                                                                   |
|                                        | Tuberculosis                     | Influenza virus                                                                   |
|                                        | Urinary tract infection:         | M. tuberculosis complex                                                            |
|                                        | cystitis, urethritis,            | E. coli, Klebsiella spp. and other enterobacteria                                |
|                                        | pyelonephritis, complications    |                                                                                   |
| Intra-abdominal compartment             | Hepatic and intra-abdominal      | Enterobacteriaceae: Escherichia coli, other species                              |
|                                        | abscesses                        | K. pneumoniae                                                                     |
|                                        | Cholecytitis                     | Obligate anaerobic bacteria: Bacteroides fragilis, Clostridium perfringens        |
| Skin and subcutaneous tissues          | Intertrigo                       | Candida spp.                                                                      |
|                                        | Skin lesions                     | Vanella-Zoster virus                                                              |
|                                        | Cellulitis                        | S. aureus                                                                         |
|                                        | Superficial mycoses and          | S. pyogenes                                                                       |
|                                        | onychomycosis                     | Dermatophytes                                                                     |
| Soft tissue, bones, joints             | Necrotizing fascitis             | S. pyogenes; S. aureus, Enterobacteriaceae                                        |
|                                        | Diabetic foot                    | Obligate anaerobic bacteria: Bacteroides spp., Clostridium perfringens Vibrio spp.|
|                                        | Osteomyelitis, septic arthritis  | Aeromonas spp.                                                                    |
|                                        | Community-acquired and           | Salmonella spp.                                                                   |
|                                        | hospital-acquired                | Enterococcus spp.                                                                 |
|                                        |                                  | S. pyogenes, S. aureus, Gram-negative bacilli, anaerobic bacteria, fungi          |
|                                        |                                  | S. aureus, M. tuberculosis complex                                                |
| Bacteremia and sepsis                  |                                  | Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, enterobacteriaceae, enterococci, Pseudomonas aeruginosa, Candida albicans, other agents |

Adapted from [68].
SGLT2 inhibitors reduce hyperglycemia by increasing urinary glucose excretion. These agents have shown significant clinical benefit with regard to weight loss, low risk of hypoglycemia, reduction in blood pressure, reduction in cardiovascular and renal events in high-risk patients, leading to their increasing popularity for T2DM. However, common to all SGLT2 inhibitors is that chronic use is associated with a definite increase in genital infections (up to 8–10% of treated patients), with the following characteristics: mild-to-moderate severity, incidence dependent on drug dosage, hence roughly proportional to the amount of urinary glucose loss, more frequent in women (vulvovaginitis) than men (balanitis), more frequent in association with obesity, antecedent history of genital infection, poor hygiene, often recurrent but seldom leading to treatment discontinuation [93]. Urinary tract infections show the same pattern, although with a lower incidence (+15% vs. placebo or non-SGLT2 medications) than genital infections (+180%).

Diabetes mellitus and environmental factors

Type 1 diabetes mellitus and environment
Potential triggers of islet autoimmunity include diet, toxins, infections that affect children (in utero, perinatally, during childhood). Comparisons between the genetically-related populations of Finland and the neighboring Karelian Republic of Russia indicate that T1DM is six times more common in Finland and that other immune mediated diseases (celiac disease, autoimmune thyroiditis, allergy) follow a similar trend [105]. Supporting the impact of environment or lifestyle on risk, migrants tend to acquire the same risk of T1DM as the population in their new area of residence [106,107]. In African migrants to France, T1DM is developing earlier compared with those staying in their country of birth [108]. Thus, environmental factors have a key role in T1DM.

Type 1 diabetes mellitus and infection
Viruses have long been suggested as environmental triggers. A meta-analysis showed a significant association between enterovirus detection in blood and T1DM at the
time of clinical onset [109]. The finding has been confirmed in multiple studies both at onset and in later phases [110–115]. The MIDIA study suggested that in genetically predisposed children enterovirus infection may precede islet autoimmunity [116]. Viral serology has shown that infection by coxsackievirus B1 is associated with islet autoimmunity and progression to clinical diabetes [117,118]. Enterovirus infection during pregnancy may have a pathogenic role [119,120]. In support of these association studies, the enterovirus capsid protein VP1 was found in islets of patients with T1DM both close to the time of onset and several years after onset, indicating that enteroviruses establish a persistent infection in beta cells [121–123]. Virus does not produce a lytic effect in islet cells, rather T1DM occurs in the presence of a persistent low-grade infection triggering an inflammatory response, beta cell damage and autoantigen release [124]. The observation that children with T1DM show an incomplete antibody response to enteroviruses [125] supports the hypothesis of defective antiviral resistance leading to a chronic infection, then to endocrine autoimmunity. Molecular and immunologic methods for detecting minute amounts of mutated enterovirus types will assist in defining diabetes-associated viruses [126,127]. As indirect evidence for enterovirus infection, viral signatures such as interferon and major histocompatibility complex class-I (MHC-I) hyperexpression have been found in T1DM [128].

Respiratory infections in children are temporally associated with initiation of islet autoimmunity in the TEDDY study [129]. Similarly, detection of enteroviruses in stools precedes islet autoimmunity [130]. Other reports document the frequent exposure to infectious agents at time points close to the clinical onset of T1DM [131]. Later, progressive beta cell loss may be secondary to activation of autoreactive mechanisms [124]. Among mechanisms leading to virus-induced autoimmunity and beta cell death, molecular mimicry reflects the possible cross reactivity between viral components and islet proteins [124]. Additional mechanisms include epitope spreading, bystander activation, bystander damage.

Rare variants of IFIH1, a gene implicated in antiviral responses, have been shown to protect from or predispose to T1DM [132], thus confirming the possible role of viruses in initiating the diabetogenic process [133,134]. Should enteroviruses be pathogenic contributors to T1DM, efforts at developing effective antivirals and an enterovirus vaccine will be of utmost importance [135–137].

Additional factors possibly involved in the origin of T1DM include breastfeeding [138], exposure to cow milk [139], exposure to Mycobacterium avium-paratuberculosis in bovine milk [140], timing of introduction of cereals [141] or egg [142], toxic chemicals such as nitrates and derivatives [143], vitamin D intake during pregnancy and thereafter [115,144]. Recently, tenuous evidence has been published for a possible causative role of influenza viruses [145].

**Fulminant diabetes**

Fulminant T1DM (FDM) was first reported by Imagawa [146]. FDM is defined as remarkably abrupt onset; very short duration of hyperglycemic symptoms (less than 1 week); ketoacidosis at diagnosis; negativity of islet-related autoantibodies; almost nil C-peptide; elevated levels of pancreatic enzymes; high ratios of glycated albumin to glycated hemoglobin (indicating that hyperglycemia was of short duration) [147]. These characteristics are found in about 20% new cases in Japan. Influenza-like symptoms are frequent before the onset [148]. FDM may be associated with pregnancy [149], leads to early microvascular damage, is associated with HLA DRB1*04:05DQB1*04:01 [147] and autoantibodies to C300 (a protein family expressed in dendritic cells [150]. FDM has been reported from Korea, China, other areas of Asia, and – sporadically – in whites [151]. Notably, titers of enterovirus IgA antibodies were elevated in patients with recent-onset FDM compared with those with recent-onset autoimmune T1DM [151]. Enterovirus antigens are detected in islets and exocrine tissue together with upregulation of MDAs, RIG-I, TLR3, and TLR4 [148]. Features of FDM point to a short pathogenic process of infectious origin leading to rapid beta cell destruction.

**Enteroviruses in waters**

Health risks associated with sewage-contaminated waters are a public health concern. Water monitoring systems rely predominantly on the enumeration of bacterial indicators. However, human enteric viruses – due to their resilience and persistence in the environment – may represent more significant indicators. In Hawaiian waters, 11/20 sites tested positive for enteroviruses, indicating fecal contamination. In addition, shellfish from six of nine sites tested positive for enteroviruses of different species [152]. In the context of poliovirus surveillance, waters examined for polio and nonpolio enteroviruses in Helsinki (Finland) and Islamabad (Pakistan) contained multiple nonpolio enteroviruses, predominantly of the B species (coxsackieviruses and select echoviruses) [153]. Comparable results have been obtained in Varese, Italy: diverse nonpolio enterovirus types have been detected in sewage and wastewater, belonging mostly to the B species and the Echovirus group (unpublished observations). Importantly, enteroviruses were not found in drinking waters. In contrast, in Egypt nonpolio enteroviruses were found in 100% sewage and wastewater and also in one third of drinkable water samples [154]. It has also been proposed that enteroviruses may persist in free-living amoebae within environmental waters [155]. Thus, waters may represent a common vehicle of transmission for these agents and could contribute to the spreading of diabetes mellitus.
The hygiene hypothesis in type 1 diabetes mellitus

Over the last century, improved hygienic conditions have led to reduced circulation and exposure to biological agents (pathogens, commensals, parasites). This may have resulted in lessened antimicrobial immunity with consequences possibly relevant to the young and older ages [97,156]. In addition, vaccines could reduce communicable diseases. These events correlate with the heightened frequency of autoimmune conditions and the increasing incidence of common infections at older ages [156,157]. Lack of intestinal parasites seems particularly linked to autoimmune conditions [78,158] and helminth-induced immunomodulation may well prevent diabetes mellitus and ameliorate insulin sensitivity [159,160].

Type 2 diabetes mellitus and environment

Epidemiologically, high levels of walkability and green space are associated with lower T2DM risk, while increased levels of air pollution and noise are associated with greater risk [161]. Thus, an important risk factor is urbanization itself, which is linked to consumption of unhealthy foods, sedentary lifestyle, scarce exposure to sunlight. Randomized controlled trials in Finland, USA, China, and India established that lifestyle modification with physical activity [162] and healthy diets [163] can delay or prevent T2DM. A variety of environmental factors may play a role in T2M. These include: delivery mode, weight at birth, placental function, maternal nutrition, postnatal growth, antibiotic usage, diet with processed foods, calorie intake, macro, and micronutrients, vitamins, basal metabolism, exercise, sleep debt, endocrine disruptors, chronic inflammation [164]. To prevent T2DM, WHO recommends limiting saturated fatty acid consumption to less than 10% of total energy intake and achieving adequate intake of dietary fiber (minimum 20 g daily). Reducing the intake of free sugars to less than 10% of total and physical activity 3–5 days a week for at least 30–45 min are also recommended [2].

Gut microbiome

Though medicine is mostly concerned with pathogenic bacteria, a symbiotic interaction of intestinal bacteria with the human body forges the immune system. Gut microbes participate in polysaccharide breakdown, nutrient absorption, gut permeability, bile acid modification, inflammatory responses, and may produce vitamins and nutrients. In the distal gut microbiota, more than 90% of phylogenetic types belong to two divisions: the Firmicutes (mostly Gram-positive) and the Bacteroidetes (Gram-negative, nonsporeforming, rod-shaped bacteria). The remaining types are distributed among eight divisions. Alterations in Gammaproteobacteria (Gram-negative) and Verrucomicrobia (Gram-negative) and the ratios of Firmicutes to Bacteroidetes (Gram-positive) are associated with weight gain and insulin resistance, while alterations in butyrate-producing bacteria (e.g., Roseburia spp., Clostridium spp., Eubacterium rectale, Faecalibacterium prausnitzii – all Gram-positive) could contribute to diabetes mellitus [165]. Butyrate is thought to cause beneficial effects through enhancement of mitochondrial activity, activation of intestinal gluconeogenesis, prevention of metabolic endotoxemia [166].

In patients with T1DM or other autoimmune conditions a reduced diversity of microbiota has been reported [167]. Dysbiosis is also associated with T2DM [168]. Some bacterial groups seem related to plasma glucose concentrations, including the ratio of Bacteroidetes to Firmicutes and the ratio of Bacteroides-Prevotella to Clostridium cocoides and Eubacterium rectale. It is supposed that a microbiome enriched in the Gram-negative component (e.g., Proteobacteria) may release more LPS, thereby stimulating Toll-like receptors that induce a proinflammatory status [169]. Most of these studies have been performed with stool samples and are not representative of the small intestine that is preferentially linked to pancreas. Taken together, the results indicate that there is no well delineated bacterial taxon serving as a general marker for diabetes mellitus or one that can even be suspected of a causal influence in diabetogenesis. Bacteriome alterations could indeed be an effect of increased glycemia, its excursions, dietary changes following diagnosis, diabetes medications.

Other infections possibly linked with diabetes

Hepatitis C virus

In the United States, an estimated 9.4% of the population has diabetes mellitus and 1.4% carries hepatitis C virus (HCV) [170]. T2DM is nearly four times more likely to develop in HCV-positive than in HCV-negative individuals [171]. Thus, anti-HCV treatments have the potential to impact a remarkable proportion of the population not only regarding liver disease but also diabetes mellitus [172]. In fact, glycemic control may improve in people with diabetes who are treated with antivirals due to the HCV carrier status. Not only HbA1c levels improve, but insulin requirement is also reduced. Future studies will determine the duration of metabolic improvement in diabetes mellitus patients treated with antivirals and the effect of this treatment on complications [173]. In vitro, HCV may infect pancreatic islet cells. Infected islets have altered cytokine expression that may well contribute to insulin deficiency [174].

Prion-like protein aggregates in diabetes

Prions are infectious agents devoid of nucleic acids that cause progressive neurodegenerative diseases with long incubation times (usually years). Prion disease can be initiated by a spontaneous event, transmitted through genetic inheritance, through body fluids and/or excreta, contact with the contaminated environment or food, medical intervention [175]. Prion diseases are
characterized by the accumulation of amyloid in tissues and are classified as protein misfolding disorders (PMDs).

Cats are one of the few species that develop a form of diabetes mellitus analogous to T2DM. The characteristic finding in cats with T2DM is deposition within islets of amyloid derived from the beta cell hormone amylin (islet amyloid polypeptide, IAPP). Increased IAPP concentration has been documented in islet cells and plasma of diabetic cats, supporting a pathogenic role for the polypeptide [176].

As in cats, the accumulation in islets of IAPP aggregates is a frequent finding in people with diabetes. IAPP aggregates promote the misfolding of endogenous IAPP in cultured islets, and inoculation of IAPP aggregates into transgenic mice expressing human IAPP accelerates amyloid deposition in islets. The phenomenon is accompanied by hyperglycemia and reduction of beta cell mass. Thus – if indeed a PMD – T2DM could be transmissible through mechanisms proper to the spread of prions in neurologic disease [177].

Beta cell dysfunction and abnormal blood glucose concentrations have been reported in rodents infected with scrapie prions [178]. The cellular prion protein (PrPC) is expressed in beta cells and appears to contribute to glucose homeostasis. Pancreatic iron stores are influenced by PrPC expression. Silencing of PrPC resulted in significant depletion of intracellular iron and upregulation of the glucose transporter GLUT2 and insulin. Iron overload, on the other hand, resulted in downregulation of GLUT2 and insulin in a PrPC-dependent manner. Glucose intolerance develops in iron-overloaded PrP+/+ but not in PrP−/− mice, indicating that PrPC-mediated modulation of intracellular iron does influence both insulin secretion and insulin sensitivity of target organs. Thus, the PrPC protein (and possibly its abnormal variants) appear to play a role in glucose homeostasis [179]. Current research is exploring the mechanism underlying the prion-like transmission of IAPP aggregates and its possible role in T2DM [180].

Vaccines for people with diabetes

As reported above, diabetes mellitus confers enhanced risk of morbidity and mortality from a variety of infectious conditions [181]. Pneumococcal disease (including community-acquired pneumonia and invasive pneumococcal disease) poses a burden all year round. Thus, pneumococcal vaccination of people with diabetes should be started at any time of the year [182,183]. Currently, the CDC recommends the following vaccinations for people with diabetes (www.immunize.org/catg.d/p4043.pdf): seasonal flu vaccine: every year; pneumococcal vaccines (13-valent and 23-valent); hepatitis B vaccine series, Tdap vaccine (tetanus, diphtheria, and pertussis); Zoster vaccine after 50 years of age. Other vaccines may be administered if needed: hepatitis A, measles, mumps, rubella, varicella, papillomaviruses, hemophilus influenzae type b, meningococci of the ACWY and B types. It should not be underestimated that infectious conditions may hinder glucose homeostasis and require accurate metabolic control.

Recently, interest in the old TB vaccine bacillus calmette-guérin (BCG) has been revived for possible use in T1DM. Clinical trials are testing the value of BCG in prevention and treatment of adult patients. BCG induces a host response – driven in part by tumour necrosis factor – that aims at eliciting selective death of autoreactive T cells with the concurrent expansion of beneficial Tregs. Preliminary results are promising [186,187]. BCG should also be considered for TB prevention in countries at high incidence of both diabetes mellitus and TB such as India and China [188–190].

Conclusion

Evidence points to a bidirectional link of diabetes mellitus with infectious agents (viral, bacterial, fungal, parasitic, prion-like). On one hand, genetics and metabolic changes predispose people with diabetes to infectious events of varying severity. Notably, over a life time, the enhanced susceptibility of people with diabetes to infections tends to expose them to a substantial consumption of antimicrobials, facilitating the selection of drug-resistant strains. On the other hand, poorly identified biologic agents may participate in the pathogenic processes that lead to diabetes mellitus. As genetic predisposition cannot be changed, it will be crucial to identify the environmental factors that play an etiologic/triggering role in diabetes mellitus. Thus, clinical microbiology laboratories are encouraged to implement research and monitoring programs for diabetic people.

Should investigations continue to support the assumption that infections play a causative role in diabetes mellitus, then interventions should target the latter factors. However, even if some diabetes mellitus forms will be accepted as transmissible, NCDs will remain with us for a long time shaping the future of global health.
Acknowledgements

The opinions expressed in this publication are those of the authors. They do not necessarily reflect the opinions or views of funding Agencies.

Study supported by: the Italian Ministry of Health (PE-2013-02357094 to A.T.), JDFR & nPOD-V (3-SRA-2017-492-A-N, subrecipient A.T.). Study conducted in collaboration with the Centro Linceo Beniamino Segre, Accademia dei Lincei, Rome, Italy.

Conflicts of interest

There are no conflicts of interest.

References

1. Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med 2013; 369:1336–1343.
2. Internationl Diabetes Federation. IDF diabetes atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017.
3. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 2018; 41:S13–S27.
4. Laugesen E, Ostergaard JA, Leslie RD, Danish Diabetes Academy. Noncommunicable diseases. N Engl J Med 2013; 369:1336–1343.
5. Polonsky KS. Genetics of type 1 diabetes. Diabetes Care 2011; 34:1332–1340.
6. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge AW, Malanda B. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138:271–281.
7. Knip M. Pathogenesis of type 1 diabetes: implications for incidence trends. Horm Res Paediatr 2011; 76 (Suppl 1):57–64.
8. Catanzariti L, Faulks K, Moon L, Waters AM, Flack J, Craig ME. Australia’s national trends in the incidence of type 1 diabetes in 0-14-year-olds, 2000–2006. Diabet Med 2009; 26:596–601.
9. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 2018; 41:917–928.
10. Scalone L, Cesana G, Furneri G, Ciampichini R, Beck-Peccoz P, Chiodini V, et al. Burden of diabetes mellitus estimated with a longitudinal population-based study using administrative databases. PLoS One 2014; 9:e113741.
11. Perry DJ, Wessellall CH, Oram RA, Williams MD, Posgai A, Murr AB, et al. Application of a genetic risk score to racially diverse type 1 diabetes populations demonstrates the need for diversity in risk-modeling. Sci Rep 2018; 8:4529.
12. Hivert MF, Vassy JL, Meigs JB. Susceptibility to type 2 diabetes mellitus – from genes to prevention. Nat Rev Endocrinol 2014; 10:198–205.
13. Yeung RO, Hannah-Shmouni F, Niederhofer K, Walker MA. Not quite type 1 or type 2, what now? Review of monogenic, mitochondrial, and syndromic diabetes. Rev Endocr Metab Disord 2018. doi:10.1007/s11154-018-9446-3. [Epub ahead of print].
14. Robertson CC, Rich SS. Genetics of type 1 diabetes. Curr Opin Genet Dev 2018; 50:7–16.
15. Afshieh S, Elding Larsson E, Ivansson S-A, Lernmark A. Ch. 10. In: Holt RIGG, Cockram CS, Flyvbjerg A, Goldstein B, editors. Textbook of diabetes John Wiley and Sons, Ltd.; 2017: pp. 143–153.
16. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet 2018; 391:2449–2462.
17. Jerram ST, Leslie RD. The genetic architecture of type 1 diabetes. Genes 2017; 8:doi:10.3390/genes8080209.
18. Perez De Nancalares G, Bilbao JR, Calvo B, Vitoria JC, Vazquez F, Castano L, S-Insulin gene VNTR polymorphism is specific for type 1 diabetes: no association with celiac or Addison’s disease. Ann NY Acad Sci 2003; 1005:319–323.
19. Sharp RC, Abrahamson M, Naser ES, Naser SA. Genetic Varia
tions of PTPN2 and PTPN22: Role in the Pathogenesis of Type 1 Diabetes and Crohn’s Disease. Front Cell Infect Microbiol 2015; 5:95.
20. Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annu Rev Immunol 2015; 33:417–443.
21. Tomita T. Apoptosis in pancreatic beta- islet cells in Type 2 diabetes. Bosn J Basic Med Sci 2016; 16:162–179.
22. Parkkola A, Laine AP, Pennanen H, Hakonen T, Kakkarainen S, Ilonen J, et al. HLA and non-HLA genes and familial predisposition to autoimmune diseases in families with a child affected by type 1 diabetes. PloS one 2017; 12:e0188402.
23. Soleimannpaur SA, Ferrari AM, Raum JC, Groff DN, Yang J, Kaufman BA, et al. Diabetes Susceptibility Genes Pdx1 and Clec16a Function in a Pathway Regulating Mitophagy in beta-Cells. Diabetes 2015; 64:3473–3484.
24. Lemos NE, Dieter C, Dorfman LE, Assmann TS, Duarte GCK, Canani LH, et al. The rs2292239 polymorphism in ERBB3 gene is associated with risk for type 1 diabetes mellitus in a Brazilian population. Gene 2016; 644:122–128.
25. Floyet T, Briesson C, Nielsen LR, Mann M, Bang-Berthelsen CH, Friedrichsen M, et al. CTH regulates beta-cell function and disease progression in newly diagnosed type 1 diabetes patients. Proc Natl Acad Sci USA 2014; 111:10305–10310.
26. Jermendy A, Szatmary J, Kamer A, Szabo AI, Toth-Hevny P, Hermann R. Association between interferon-induced helicase (IFIH1) rs1990760 polymorphism and seasonal variation in the onset of type 1 diabetes mellitus. Pediatr Diabetes 2018; 19:300–304.
27. Dendrou CA, Cortes A, Shipman L, Evans HG, Attfield KE, Jostins L, et al. Resolving T1Y2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med 2016; 8:363ra349.
28. Redondo MJ, Steck AK, Pugliese A. Genetics of type 1 diabetes. Pediatr Diabetes 2018; 19:346–353.
29. Prasad RB, Groop L. Type 2 diabetes. In: Holt RIGG, Cockram CS, Flyvbjerg A, Goldstein B, editors. Textbook of diabetes John Wiley & Sons, Ltd.; 2017: pp. 187–204.
30. Langenberg C, Lotta LA. Genomic insights into the causes of type 2 diabetes. Lancet 2018; 391:2463–2474.
31. Astiarraga B, Chueire VB, Souza AL, Pereira-Moreira R, Monte Alegre S, Natali A, et al. Effects of acute NFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes. Diabetologia 2018; 61:1829–1837.
32. Chen X, Ayala I, Shannon C, Fourcaudot M, Achariya NK, Jenkinson CP, et al. The Diabetes Gene and Wnt Pathway Effector TCF7L2 Regulates Adipocyte Development and Function. Diabetes. 2018; 67:554–568.
33. Manoharan I, Hong Y, Suryawanshi A, Angus-Hill ML, Sun Z, Mellor AL, et al. TLK2-dependent activation of beta-catenin pathway in dendritic cells induces regulatory responses and attenuates autoimmune inflammation. J Immunol 2014; 193:4203–4213.
34. Langenberg KA, MA L, Sharma NK, Hanis CL, Elbein SC, Hasstedt SJ, et al. Single nucleotide polymorphisms in JAZF1 and BCL11A gene are nominally associated with type 2 diabetes in African-American families from the GENNID study. J Hum Genet 2012; 57:67–71.
57. Stegenga ME, van der Crabben SN, Blümer RM, Levi M, Zwang TJ, Gormally MV, Johal MS, Sazinsky MH.

56. Montoya-Rosales A, Castro-Garcia P, Torres-Juarez F, Enciso-Lima A, Iborra RT, Pinto RS, Castilho G, Sartori CH, Martinez N, Kornfeld H.

55. Tan KS, Lee KO, Low KC, Gamage AM, Liu Y, Tan GY, Hu R, Xia CQ, Butfiloski E, Clare-Salzler M.

54. Collison KS, Parhar RS, Saleh SS, Meyer BF, Kwaasi AA, Meijers JC, Serlie MJ, Galan BE, Tack CJ, et al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002; 71:433–444.

53. Machado-Lima A, Iberra RT, Pinto RS, Castilho G, Sartori CH, Martinez N, Kornfeld H.

52. Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eisenbach K, et al. A catch-22: interleukin-22 and cancer. Eur J Immunol 2018; 48:15–31.

51. Montoya-Rosales A, Castro-Garcia P, Torres-Juarez F, Enciso-Lima A, Iberra RT, Pinto RS, Castilho G, Sartori CH, Martinez N, Kornfeld H. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002; 71:433–444.

50. Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eisenbach K, et al. A catch-22: interleukin-22 and cancer. Eur J Immunol 2018; 48:15–31.

49. Jafar N, Edriss H, Nugent K. The effect of short-term hyperglycemia on the innate immune system. Am J Med Sci 2016; 351:201–211.

48. Ghosh P, Vaidya A, Sahoo R, Goldfine A, Herring N, Bly I, et al. Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans. J Clin Endocrinol Metab 2014; 99:E156–E160.

47. Plomashenko MA, Low KC, Camilleri G, Williams JS, Infections associated with diabetes. In: Holt RM, Cockram CS, Flyvbjerg A, Goldstein BJ, editors. Textbook of diabetes John Wiley & Sons, Ltd.; 2017:pp. 799–820. Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, Jarlier V, et al. Antimicrobial immunity and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health 2018; 6:e619–e629.

46. Wagger DH Jr. Overlooked mechanisms in type 1 diabetes etiology: how unique costimulatory molecules contribute to diabetogenesis. Front Endocrinol (Lausanne) 2017; 8:208.

45. Snijders T, Kusters P, Engel D, Lugtenberg E, CD40-CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications. Diab Vasc Dis Res 2013; 10:113–122.

44. DeFrancesca F, Belkina AC, Jagannathan-Bogdan M, Snyder-Caprio P, Cell Metab 2011; 13:208–213.

43. Kajiwara C, Kusaka Y, Kimura S, Yamaguchi T, Nanjo Y, Ishii MB, et al. Regulatory T cell dysfunction in type 1 diabetes: what’s broken and how can we fix it? J Diabetes 2017; 9:1839–1850.

42. Martinez N, Kornfeld H.

41. Martinez N, Kornfeld H.

40. Lewis ND, Asim M, Barry DP, de Sablet T, Singh K, Piazuelo MB, et al. Immune evasion by Helicobacter pylori is mediated by induction of macrophage arginase II. J Immunol 2011; 186:362–369.

39. Szendroedi J, Yoshimura T, Phielix E, Koliaki C, Marcucci M, In: Holt RM, Cockram CS, Flyvbjerg A, Goldstein BJ, editors. Textbook of diabetes John Wiley & Sons, Ltd.; 2017:pp. 799–820. Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, Jarlier V, et al. Antimicrobial immunity and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health 2018; 6:e619–e629.

38. Rutter GA, Chimienti F, Slc30a8 mutations in type 2 diabetes. Diabetologia 2015; 58:31–36.

37. Szenzodori J, Yoshimura T, Phielix E, Koliaki C, Marcucci M, Zhang D, et al. Role of diacylglycerol activation of PKCtheta in lipid-induced muscle insulin resistance in humans. Proc Natl Acad Sci USA 2014; 111:9397–9402.

36. Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol 2014; 44:617–626.

35. Kajiwara C, Kusaka Y, Kimura S, Yamaguchi T, Nanjo Y, Ishii MB, et al. Metformin mediates protection against legionella pneumonia through activation of AMPK and mitochondrial reactive oxygen species. J Immunol 2018; 200:623–631.

34. Rouleau G, Kontoyiannis DP, Tack CJ, Host defenses against zygomycetes. Clin Infect Dis 2012; 54 (Suppl 1):S61–S66.

33. Wong SL, Wagner DD. Pelpetidylamine deiminase 4: a nuclear button triggering neutrophil extracellular traps in inflammatory diseases and aging. FASEB J 2018; e201800619R. doi:10.1096/fj.201800619R. [Epub ahead of print].

32. Lachmandas E, Thiem K, van den Hevel C, Hijmans A, de Galan BE, Tack CJ, et al. Patients with type 1 diabetes mellitus have impaired IL-1beta production in response to Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 2018; 37:371–380.

31. Collison KS, Parhar RS, Saleh SS, Meyer BF, Kwaasi AA, Hammann MM, et al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002; 71:433–444.

30. Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eisenbach K, et al. A catch-22: interleukin-22 and cancer. Eur J Immunol 2018; 48:15–31.

29. Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eisenbach K, et al. A catch-22: interleukin-22 and cancer. Eur J Immunol 2018; 48:15–31.

28. Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eisenbach K, et al. A catch-22: interleukin-22 and cancer. Eur J Immunol 2018; 48:15–31.

27. Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eisenbach K, et al. A catch-22: interleukin-22 and cancer. Eur J Immunol 2018; 48:15–31.

26. Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eisenbach K, et al. A catch-22: interleukin-22 and cancer. Eur J Immunol 2018; 48:15–31.

25. Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eisenbach K, et al. A catch-22: interleukin-22 and cancer. Eur J Immunol 2018; 48:15–31.

24. Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eisenbach K, et al. A catch-22: interleukin-22 and cancer. Eur J Immunol 2018; 48:15–31.
80. Lee MR, Huang YP, Kuo YT, Luo CH, Shih YJ, Shu CC, et al. Diabetes mellitus and latent incipient insulin resistance: a systematic review and meta-analysis. *Clin Infect Dis* 2017; 64:719–727.

81. Malik F, Mehdi SF, Ali H, Patel P, Basharat A, Kumar A, et al. Is metformin poised for a second career as an antimicrobial? *Diabetes Metab Res Rev* 2018; 34:e2975.

82. McKane CK, Marmarellis M, Mendu ML, Moromizato T, Gibbons FK, Christopher KB. Diabetes mellitus and community-acquired bloodstream infections in the critically ill. *J Crit Care* 2014; 29:7c.

83. Trevelin SC, Carlos D, Beretta M, da Silva JS, Cunha FQ. Diabetes mellitus and sepsis: a challenging association. *Shock* 2017; 47:276–287.

84. Frydrych LM, Fattahi F, He K, Ward PA, Delano MJ. Diabetes and sepsis: risk, recurrence, and ruination. *Front Endocrinol* 2017; 8:271.

85. Taganna J, de Boer AR, Wubmer N, Bouckaert J. Glycosylation changes as important factors for the susceptibility to urinary tract infection. *Biochem Soc Trans* 2011; 39:349–354.

86. Mikamo H, Yamagishi Y, Sugiyama H, Sadakata H, Miyazaki T. Association of metabolic factors with dengue viral infection on admission triage which predict its clinical course during Lahore dengue epidemic. *J Pak Med Assoc* 2016; 66:1100–1106.

87. Wang Z, Ren J, Wang G, Liu Q, Guo K, Li J. Association between diabetes mellitus and outcomes of patients with sepsis: a meta-analysis. *Med Sci Monit* 2017; 23:3546–3555.

88. Baig Mirza AM, Fida M, Martaza G, Niazi R, Hani R, Irfan K, Masud F. Association of metabolic factors with dengue viral infection on admission triage which predict its clinical course during Lahore dengue epidemic. *J Pak Med Assoc* 2016; 66:1100–1106.

89. Bongiorno D, Mongelli G, Stefani S, Campanile F. Burden of rifampicin- and methicillin-resistant *Staphylococcus aureus* in Italy. *Microb Drug Resist* 2018; 24:732–738.

90. Honkavaara C, Kodama S, Fujihara K, Hirazawa R, Yachi Y, Suzuki A, et al. High risk of failing eradication of *Helicobacter pylori* in patients with diabetes: a meta-analysis. *Diabetes Res Clin Pract* 2014; 106:81–87.

91. Hirji J, Anderson SW, Guo Z, Hammam N, Gomez-Camneno A. Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database. *J Diabetes Complications* 2012; 26:501–505.

92. Nyirepsy P, Sobel JD, Fung A, Mayer C, Capuano G, Wysy K, Usiskin K. Genital mycotic infections as important factors for the susceptibility to urinary tract infections in pregnancy and type 1 diabetes in their offspring: a systematic review and meta-analysis of observational molecular studies. *BMJ* 2011; 342:c15.

93. Schulte BM, Bakkers J, Lanke KH, Melchers WJ, Westerlaken B, Oikarinen S, Martiskainen M, Tauriainen S, Huhtala H, Ilonen J, Knip M, Miettinen PJ. Diabetes mellitus and community-acquired bloodstream infections in the critically ill. *Diabetes Res Clin Pract* 2018; 121:478–493.

94. Lehtonen J, Nurminen N, Laitinen OH, Isolikkin S, Toniolo H, Miettinen PJ. Diabetes mellitus and infections in pregnancy and type 1 diabetes in their offspring: a systematic review and meta-analysis of observational molecular studies. *BMJ* 2011; 342:c15.

95. Chen HH, Lin JC, Chen HJ, Yeh SY, Kao CH. Association of herpes zoster and type 1 diabetes mellitus. *PLoS One* 2016; 11:e0155175.

96. Papagianni M, Metallidis S, Tziomatos K. Herpes zoster and diabetes mellitus: a review. *Diabetes Ther* 2018; 9:454–530.

97. Kim MC, Yun SC, Lee SO, Choi SH, Kim YS, Woo JH, Kim SH. Statins increase the risk of herpes zoster: a propensity score-matched analysis. *PLoS One* 2018; 13:e0196263.

98. Vardulas KZ, Horizonopoulos M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. *Diabetes Res Clin Pract* 2008; 80:344–351.

99. Masud F. Diabetes mellitus and community-acquired bloodstream infections in the critically ill. *J Crit Care* 2014; 29:7c.

100. Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. *Mayo Clin Proc* 2017; 92:1806–1821.
Viruses in type 1 diabetes.

Hakola L, Takkinen HM, Niinisto S, Ahonen S, Nevalainen J, Veijola R, et al. Infant feeding in relation to the risk of advanced islet autoimmunity and type 1 diabetes in children with increased genetic susceptibility: a cohort study. *Am J Epidemiol* 2018; 187:34–44.

Benson VS, Van Reenen JA, Taylor J, Somers GS, McKinney PA, Van Til L. Type 1 diabetes mellitus and components in drinking water and diet: a population-based, case-control study in Prince Edward Island, Canada. *Am Coll Nutr* 2010; 29:612–624.

Dong JY, Zhang WG, Chen JJ, Zhang ZL, Han SF, Qin LQ. Vitamin D intake and risk of type 1 diabetes: a meta-analysis of observational studies. *Nutrients* 2013; 5:3551–3562.

Capela I, Mercalli A, Romero-Tejeda A, Pizarro E, Soto MD, Testa PA, et al. Study of 2009 H1N1 pandemic influenza virus as a possible causative agent of diabetes. *Clin Endocrinol Metab* 2018. doi:10.1210/clin.cen-2018-000862.

Hanauska T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. *Nat Clin Pract Endocrinol Metab* 2007; 3:36–45.

Liu L, Zeng J, Sang D, Lu Z, Shen J. Recent findings on fulminant type 1 diabetes. *Diabetes Metab Res Rev* 2018; 34:doi:10.1002/dmrr.2928.

Shibasaki S, Imagawa A, Hanauska T. Fulminant type 1 diabetes mellitus: a new class of type 1 diabetes. *Adv Exp Med Biol* 2012; 771:20–23.

Inagaki T, Nishi Y, Suzuki N, Suzuki S, Koizumi Y, Azaiwa T, Hashizume K. Fulminant diabetes mellitus associated with pregnancy: case reports and literature review. *Endocr J* 2002; 49:319–322.

Haseda F, Imagawa A, Nishikawa H, Mitsui S, Tsutsumi C, Fujisawa K, et al. Antibody to CMV F55-like molecule 2, CD300e a novel biomarker detected in patients with fulminant type 1 diabetes. *Plos One* 2016; 11:e0160576.

Imagawa A, Hanauska T. Fulminant type 1 diabetes – an important subtype in East Asia. *Diabetes Metab Res Rev* 2011; 27:959–964.

Connel C, Tong HI, Wang Z, Allmann E, Lu Y. New approaches for enhanced detection of enteroviruses from Hawaiian environmental waters. *Food Environ Virol* 2011; 3:959–964.

Furtak V, Roviainen M, Mirochnichenko O, Zagorodnyaya T, Laasri M, Zaidi SZ, et al. Environmental surveillance of viruses by tangential flow filtration and metagenomic reconstruction. *Euro Surveill* 2016; 21:doi:10.2807/1560-7917.es.2016.21.15.30193.

El-Senousy WM, Abdel-Moneim A, Abdel-Latif M, El-Heinawy MB, Khalil RG. Coxsackievirus B4 as a causative agent of diabetes mellitus type 1: Is there a role of inefficiently treated drinking water and sewage in virus spreading? *Food Environ Virol* 2018; 10:89–98.

Atanasova ND, Day R, Scott C, Li Q, Pang XL, Ashbolt NJ. Persistence of infectious Enterovirus within free-living amoebae – a novel waterborne risk pathway? *Water Res* 2018; 144:204–214.

Lambrecht BN, Hammed H. The immunology of the allergy epidemic and the hygiene hypothesis. *Nat Immunol* 2017; 18:1076–1083.

Varyani F, Fleming JO, Maizels RM. Helminths in the gastrointestinal tract as modulators of immunity and pathology. *Am J Physiol Gastrointest Liver Physiol* 2013; 312:G537–G549.

de Ruiter K, Tahapary DL, Bartojo E, Ehrlich HC, Superti F, et al. Helminths, hygiene hypothesis and type 2 diabetes. *Parasite Immunol* 2017; 39:doi:10.1111/par.12404.

Berbudi A, Ayder J, Wardani AP, Hoerauf A, Hubner MP. Parasitic helminths and their beneficial impact on type 1 and type 2 diabetes. *Diabetes Metab Res Rev* 2016; 32:236–250.

Wang M, Wu L, Zheng W, Wu Z, Lv Z. Therapeutic potential of helminths in autoimmune diseases: helminth-derived immune-regulators and immune balance. *Parasitol Res* 2017; 116:2065–2074.

Dendup T, Feng X, Clingan S, Astell-Burt T. Environmental risk factors for developing type 2 diabetes mellitus: a systematic review. *Int J Environ Res Public Health* 2018; 15:doi:10.3390/ijerph15101078.

Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. *BMJ* 2008; 336:1100–1108.
163. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol* 2018; 14:88–98.

164. Franks PW, McCarthy MI. Exposing the exposures responsible for type 2 diabetes and obesity. *Science* 2016; 354:69–73.

165. Barlow GM, Yu A, Mathur R. Role of the gut microbiome in obesity and diabetes mellitus. *Nutr Clin Pract* 2015; 30:787–797.

166. Harstena AV, Bouter KE, Backhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. *Diabetes Care* 2015; 38:159–165.

167. Bach JF. The hygiene hypothesis in autoimmunity: the role of pathogens and commensals. *Nat Rev Endocrinol* 2018; 18:105–120.

168. Vatanen T, Kostic AD, d’Hennezel E, Siljander H, Franzosa EA, et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. *Cell* 2016; 165:842–853.

169. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. *Hepatology* 2015; 62:1353–1363.

170. Fabbri S, Fallahi P, Ferreri SM, Miccoli M, Antonelli A. Hepatitis C virus infection and development of type 2 diabetes mellitus: systematic review and meta-analysis of the literature. *Rev Endocr Metab Disord* 2018. doi:10.1007/s11154-017-9440-1.

171. Polo ML, Laufer N. Extrahuman manifestations of HCV: the role of direct acting antivirals. *Expert Rev Anti Infect Ther* 2017; 15:717–746.

172. Hum J, Jou HJ, Green PK, Berry K, Lundblad J, Hettinger BD, et al. Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus. *Diabetes Care* 2017; 40:1173–1180.

173. Blackard JT, Kong L, Lombardi A, Homann D, Hammerstad SS, Tomer Y. A preliminary analysis of hepatitis C virus in pancreatic islet cells. *Virology* 2017; 414:237.

174. Mathiasen CK. Silent prions and covert prion transmission. *PLoS Pathog* 2015; 11:e1005249.

175. Lutz TA, Rand JS. Pathogenesis of feline diabetes mellitus. The veterinary clinics of North America. *Small Anim Pract* 1995; 25:527–552.

176. Mukherjee A, Soto C. Prion-like protein aggregates and type 2 diabetes. *Cold Spring Harb Perspect Med* 2017; 7: doi:10.1101/cshperspect.a024315.

177. Shashank RJ, Samika SJ, Siddharth NS. Pneumococcal vaccine in diabetes: relevance in India. *J Assoc Physicians India* 2015; 63:34–35.

178. Onodera T, Sakuho A, Tsuobo H, Itohara S. Review of studies that have used knockout mice to assess normal function of prion protein under immunological or pathophysiological stress. *Microbial Immunol* 2014; 58:361–374.

179. Ashok A, Singh N. Prion protein modulates glucose homeostasis by altering intracellular iron. *Sci Rep* 2018; 8:6556.

180. Mukherjee A, Morales-Scheiding D, Salvadores N, Moreno-Gonzalez I, Gonzalez C, Taylor-Presse K, et al. Induction of IAPP amyloid deposition and associated diabetic abnormalities by a prion-like mechanism. *J Exp Med* 2017; 214:2591–2610.

181. Hufne KD, Gallo LA, Short KR. Influenza virus and glycemic variability in diabetes: a killer combination? *Front Microbiol* 2018; 2:8461.

182. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. *Thorax* 2015; 70:984–989.

183. Shashank RJ, Samika SJ, Siddharth NS. Pneumococcal vaccine in diabetes: relevance in India. *J Assoc Physicians India* 2015; 63:34–35.

184. Goeijenbier M, van Sloten TT, Slobbe L, Mathieu C, van Genderen P, Beyer WEP, Osterhaus ADME. Benefits of flu vaccination for persons with diabetes mellitus: a review. *Vaccine* 2017; 35:5093–5101.

185. Walayat S, Ahmed Z, Martin D, Pali S, Cashman M, Dhillon S. Recent advances in vaccination of nonresponders to standard dose hepatitis B virus vaccine. *World J Hepatol* 2015; 7:2503–2509.

186. Faustman DL. TNF, TNF inducers, and TNF2 agonists: a new path to type 1 diabetes treatment. *Diabetes Metab Res Rev* 2018; 34:doi:10.1002/dmrr.2941.

187. Leong I. BCG vaccination for type 1 diabetes mellitus. *Nat Rev Endocrinol* 2018. doi: 10.1038/s41574-018-0064-7.

188. Lonnroth K, Roglic G, Harries AD. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. *Lancet Diabetes Endocrinol* 2014; 2:730–739.

189. Basnyat B, Caws M, Udwarda Z. Tuberculosis in South Asia: a tide in the affairs of men. *Multidiscip Respir Med* 2018; 13:10.